La Jolla, CA-based Cordex Pharma has invited in WBB Securities to help it take a look at its strategic alternatives. "We believe that we can best serve the interests of all our shareholders by exploring every possible alternative to enhance shareholder value," Cordex CEO Shepard Goldberg says in a release. The developer's lead therapy has an approved SPA to enter a pivotal Phase IIb/III clinical trial for the treatment of a common heart arrhythmia called paroxysmal supraventricular tachycardia. Release